Welcome to our dedicated page for Mereo Biopharma news (Ticker: MREO), a resource for investors and traders seeking the latest updates and insights on Mereo Biopharma stock.
Mereo BioPharma Group plc (NASDAQ: MREO) is a clinical-stage biopharmaceutical company whose news flow centers on rare disease drug development, regulatory interactions, and partnering activity. The company regularly issues updates on its lead programs, setrusumab for osteogenesis imperfecta (OI) and alvelestat for alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD), as well as on its collaborations for assets such as vantictumab, navicixizumab and leflutrozole.
Investors following MREO news can expect detailed announcements on clinical trial progress and results. For setrusumab, Mereo and its partner Ultragenyx have reported on Phase 3 Orbit and Cosmic studies in OI, including interim decisions by a Data Monitoring Committee, final analysis plans, and top-line outcomes showing statistically significant improvements in bone mineral density despite not meeting primary fracture endpoints. News items also cover ongoing data analyses to determine potential regulatory paths and program next steps.
For alvelestat, company updates describe regulatory milestones such as Orphan Designation from the European Commission and the FDA, Fast Track designation from the FDA for AATD-LD, and alignment with regulators on the design of a planned single global Phase 3 pivotal study. Releases also discuss partnering discussions for Phase 3 development and commercialization.
Additional MREO coverage includes quarterly and annual financial results, cash runway guidance, licensing agreements like the out-licensing of vantictumab to āshibio, and conference participation, including presentations at major healthcare investor conferences. This news page allows readers to track how clinical data, regulatory designations, partnerships, and capital position evolve over time for Mereo BioPharma’s rare disease and oncology pipeline.
Mereo BioPharma Group plc (NASDAQ: MREO) announced participation in three investor conferences in September 2021. These include the Morgan Stanley 19th Annual Global Healthcare Conference (Sept 13-14), SVB Leerink CybeRx Series (Sept 22-23), and Cantor Fitzgerald Virtual Global Healthcare Conference (Sept 30 at 9:30am ET). A live audio webcast of the fireside chat at the Cantor Fitzgerald event will be available on the Company’s website. Mereo is focused on developing innovative therapeutics for oncology and rare diseases, with notable advances in clinical trials.
Infinity Pharmaceuticals announces the appointment of Robert Ilaria, Jr. as Chief Medical Officer, leading the clinical development of eganelisib, an oral immuno-oncology therapeutic. Ilaria brings extensive oncology experience, notably from his roles at Bristol Myers Squibb and Celgene. Brian Schwartz, previously Consulting Chief Physician, transitions to the Board of Directors. The press release highlights the promising data from ongoing studies, particularly in treating bladder and triple negative breast cancers, with plans for future development and registration studies.
Mereo BioPharma (NASDAQ: MREO) announced that CEO Dr. Denise Scots-Knight will speak at the BTIG Virtual Biotechnology Conference on August 9, 2021, at 9:30 AM ET. A live audio webcast will be available on the Company’s website, with a replay accessible for two weeks.
Mereo focuses on developing therapeutics for oncology and rare diseases, with key products including etigilimab for various tumors and alvelestat for Alpha-1 antitrypsin deficiency. The Company aims to deliver improved health outcomes in these areas.
Mereo BioPharma (NASDAQ: MREO) announced positive interim data from a study of alvelestat for Bronchiolitis Obliterans Syndrome (BOS) post-hematopoietic stem cell transplantation. The Phase 1b/2 study, in collaboration with the National Cancer Institute, aims to recruit 30 patients. Initial results indicated that alvelestat was well tolerated, with six of seven patients showing stable disease. Significant reductions in the desmosine biomarker were observed, suggesting alvelestat's efficacy in inhibiting neutrophil elastase. Further analyses are planned for the upcoming ASH 2021 meeting.
Mereo BioPharma Group plc (NASDAQ: MREO) announced that CEO Dr. Denise Scots-Knight will participate in a fireside chat at the Jefferies 2021 Virtual Healthcare Conference on June 3, 2021, at 8:00 AM Eastern Time. Investors can access the live audio webcast on the company’s website, with an archived version available for two weeks post-event. Mereo focuses on developing innovative therapeutics for oncology and rare diseases, boasting a robust pipeline including etigilimab and navicixizumab for cancers, and alvelestat and setrusumab for rare diseases.
Mereo BioPharma Group plc (NASDAQ: MREO) will host a virtual R&D day on May 13, 2021, to discuss its etigilimab (Anti-TIGIT) program, focusing on studies for ovarian, cervical cancer, and sarcoma. The event features key opinion leaders and will include updates on the Phase 1b/2 ACTIVATE study and a collaboration with the Cancer Focus Fund for a clinical trial at MD Anderson Cancer Center. Mereo aims to enhance outcomes in oncology and rare diseases with its advanced product candidates.
Mereo BioPharma has announced a partnership with Cancer Focus Fund to evaluate its lead anti-TIGIT antibody, etigilimab, in a Phase 1b/2 clinical study for clear cell ovarian cancer, a rare form of the disease. The study, to be conducted at The University of Texas MD Anderson Cancer Center, will be financed with an upfront consideration of $1.5 million in Mereo shares, along with milestone payments. This collaboration marks the first investment by Cancer Focus Fund, aimed at advancing promising cancer therapies.
Mereo BioPharma Group (NASDAQ: MREO) will present at the 20th Annual Needham Virtual Healthcare Conference on April 12, 2021, at 11:00am Eastern Time. Interested parties can access a live audio webcast via the company’s website, with an archived replay available for two weeks.
Mereo focuses on oncology and rare diseases, featuring six clinical-stage product candidates. Its lead candidate, etigilimab, is in Phase 1b/2 study, while navicixizumab targets late-line ovarian cancer. The company also investigates alvelestat for Alpha-1 antitrypsin deficiency and setrusumab for osteogenesis imperfecta.
Mereo BioPharma Group plc (NASDAQ: MREO) reported a significant net loss of £163.6 million for 2020, compared to a loss of £34.8 million in 2019. Despite the challenges of the pandemic, the company enhanced its pipeline with licensing agreements for setrusumab and navicixizumab, securing substantial milestone payments. Research and development expenses decreased to £16.3 million from £23.6 million in 2019. Cash reserves stand at £23.5 million, with recent financings expected to extend its operational runway into 2024. Mereo aims for substantial milestones in 2021.
Mereo BioPharma Group plc (NASDAQ: MREO) announced participation of CEO Dr. Denise Scots-Knight in the 10th Annual SVB Leerink Global Healthcare Conference on February 25, 2021, at 8:00 am ET. A live audio webcast will be available on the company’s website and archived for two weeks post-presentation. Mereo focuses on innovative therapeutics for oncology and rare diseases, with six clinical-stage candidates, including etigilimab and navicixizumab. The company is also advancing alvelestat and setrusumab for rare diseases, aiming for significant outcomes in treatment.
FAQ
What is the current stock price of Mereo Biopharma (MREO)?
What is the market cap of Mereo Biopharma (MREO)?
